News
STE
200.81
+0.28%
0.57
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
NASDAQ · 3d ago
Weekly Report: what happened at STE last week (0408-0412)?
Weekly Report · 4d ago
Steris: Moving On, Losing Its Teeth
Steris announced the sale of its dental segment for $787 million. The divestment will have a limited impact on the overall business, but it makes strategic sense. Steris remains a solid organic growth performer, but a more attractive entry point is needed before getting involved. The company is selling the dental segment, a non-core business acquired with the purchase of Cantel.
Seeking Alpha · 5d ago
Needham Reiterates Hold on Steris
Benzinga · 04/12 08:39
Steris (STE) Receives a Hold from Needham
TipRanks · 04/11 18:35
Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)
TipRanks · 04/11 15:30
Steris Sells Dental Segment to HuFriedy Group with Conditions
TipRanks · 04/11 11:32
PEAK ROCK CAPITAL AFFILIATE SIGNS DEFINITIVE AGREEMENT TO ACQUIRE HUFRIEDYGROUP
Reuters · 04/11 11:30
STERIS to divest its dental unit for $787.5M
STERIS to divest its dental unit for $787.5M. The firm looks to focus more on its core markets. The deal is structured as an equity sale. The proceeds from the sale will be primarily used to repay debt. STERIS plc (STE) to sell its dental segment to Peak Rock Capital.
Seeking Alpha · 04/11 11:29
STERIS PLC SAYS ENTERED INTO DEFINITIVE AGREEMENT TO DIVEST DENTAL SEGMENT TO PEAK ROCK CAPITAL FOR $787.5 MLN
Reuters · 04/11 11:00
STERIS Enters Definitive Deal To Divest Its Dental Segment To Peak Rock Capital For $787.5M
The Transaction is structured as an equity sale. STERIS intends to use the proceeds primarily to repay debt. The Dental segment reported revenue of $407 million. The Transaction is anticipated to close in the first quarter of fiscal year 2025. STeris expects the resulting benefit of the sale to be approximately $0.35 per diluted share.
Benzinga · 04/11 10:59
STERIS PLC: ON A FULL YEAR RUN RATE BASIS, EXPECTS RESULTING BENEFIT OF REDUCTION IN INTEREST EXPENSE TO BE APPROXIMATELY $0.35 PER DILUTED SHARE
Reuters · 04/11 10:58
STERIS to Sell Dental Segment to an affiliate of Peak Rock Capital
STERIS plc has entered into a definitive agreement to divest its Dental segment to Peak Rock Capital for $787.5 million. Peak Rock is a leading middle-market private investment firm. The Transaction is structured as an equity sale. The Dental division reported revenue of $407 million.
Barchart · 04/11 05:58
Here's Why Steris (STE) is Poised for a Turnaround After Losing -9.06% in 4 Weeks
NASDAQ · 04/09 13:35
Weekly Report: what happened at STE last week (0401-0405)?
Weekly Report · 04/08 09:01
Weekly Report: what happened at STE last week (0325-0329)?
Weekly Report · 04/01 09:01
STE Makes Notable Cross Below Critical Moving Average
NASDAQ · 03/25 21:07
Monday Sector Laggards: Industrial, Healthcare
NASDAQ · 03/25 18:35
Weekly Report: what happened at STE last week (0318-0322)?
Weekly Report · 03/25 09:01
Globus Medical (GMED) Down 5.8% Since Last Earnings Report: Can It Rebound?
NASDAQ · 03/21 15:30
More
Webull provides a variety of real-time STE stock news. You can receive the latest news about Steris Plc through multiple platforms. This information may help you make smarter investment decisions.
About STE
STERIS plc is a provider of products and services that support patient care with an emphasis on infection prevention. The Company’s segments include Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. The Healthcare segment is focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Its Applied Sterilization Technologies (AST) segment is a third-party service provider for contract sterilization, as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Its Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma customers focused on aseptic manufacturing. Its Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems.